arrow_back Back to App

Increasing Access to Biosimilar Drugs in Medicare Program

This act aims to increase the availability of more affordable biosimilar drugs for individuals covered by Medicare. This could give patients more treatment options and potentially lower healthcare costs. A pilot program will evaluate the benefits of additional payments to providers who choose biosimilar drugs.
Key points
Establishes a 3-year nationwide demonstration project under Medicare to encourage the use of more affordable biosimilar drugs.
Healthcare providers may receive additional payments for choosing biosimilar drugs over more expensive reference products.
Participation in the project is voluntary, and additional payments will not increase costs for Medicare beneficiaries.
The goal is to reduce healthcare costs and improve access to medications for Medicare recipients.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_1352
Sponsor: Rep. Hudson, Richard [R-NC-9]
Process start date: 2023-03-03
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Increasing Access to Biosimilars Act of 2023

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_1352.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-03-03.

What are the main provisions?

Key points include:

  • Establishes a 3-year nationwide demonstration project under Medicare to encourage the use of more affordable biosimilar drugs.
  • Healthcare providers may receive additional payments for choosing biosimilar drugs over more expensive reference products.
  • Participation in the project is voluntary, and additional payments will not increase costs for Medicare beneficiaries.
  • The goal is to reduce healthcare costs and improve access to medications for Medicare recipients.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Hudson, Richard [R-NC-9].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-24.

CATEGORIES

Health